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Abstract
Finding new peptide biomarkers for stomach cancer in human sera that can be implemented into a clinically practicable
prediction method for monitoring of stomach cancer. We studied the serum peptidome from two different biorepositories.
We first employed a C8-reverse phase liquid chromatography approach for sample purification, followed by mass-
spectrometry analysis. These were applied onto serum samples from cancer-free controls and stomach cancer patients at
various clinical stages. We then created a bioinformatics analysis pipeline and identified peptide signature discriminating
stomach adenocarcinoma patients from cancer-free controls. Matrix Assisted Laser Desorption/Ionization–Time of Flight
(MALDI-TOF) results from 103 samples revealed 9 signature peptides; with prediction accuracy of 89% in the training set and
88% in the validation set. Three of the discriminating peptides discovered were fragments of Apolipoproteins C-I and C-III
(apoC-I and C-III); we further quantified their serum levels, as well as CA19-9 and CRP, employing quantitative commercial-
clinical assays in 142 samples. ApoC-I and apoC-III quantitative results correlated with the MS results. We then employed
apoB-100-normalized apoC-I and apoC-III, CA19-9 and CRP levels to generate rules set for stomach cancer prediction. For
training, we used sera from one repository, and for validation, we used sera from the second repository. Prediction
accuracies of 88.4% and 74.4% were obtained in the training and validation sets, respectively. Serum levels of apoC-I and
apoC-III combined with other clinical parameters can serve as a basis for the formulation of a diagnostic score for stomach
cancer patients.
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Introduction
Mortality rates of many cancers have not changed dramatically
in the last 20 years [1]. Early detection was shown to greatly
improve the efficacy of cancer treatment, yet detection is often
only possible after the appearance of the first clinical symptoms,
which in some cancers occurs too late for successful intervention.
This is largely due to the absence of specific and sensitive tests
that allow early screening and monitoring of cancerous states.
Therefore, the discovery of novel tumor biomarkers is increasingly
considered critical to improving cancer treatment. In the past
decade, many studies have focused on biomarker discovery. One
of the most promising sources for biomarker discovery is the
human blood, in particular serum and plasma, which can reflect
many events in the body, in real time. Yet, despite immense
efforts, only a very small number of plasma proteins have been
proven to have diagnostic value [2–5]. Frequently, these
biomarkers do not stand alone and are accompanied by other
tests for monitoring and diagnosis. Most of them are not specific
and sensitive enough for wide screen diagnosis [6,7].
One possible source of novel cancer biomarkers is the
peptidome. The rationale behind focusing on serum peptides is
based on evidence that cancer formation and development
involves change in proteins’ and peptides’ metabolism, and on
the increased availability of methodology for screening the entire
peptidome. In terms of cancer development, changes may occur in
the array of intra- and extra-cellular peptides represented in the
blood peptidome, which may be specific to the cancerous stage,
and thus have a diagnostic potential [2,4,5]. In terms of detection
technology, recent advances in MS technology enable the
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[8,9]. Indeed, previous blood peptidome studies reported an array
of signature peptides in serum that had distinguished healthy from
cancer patients (reviewed in [5]). This was shown for prostate,
bladder, breast and thyroid cancer by Villanueva et al [10,11].
They reported 61 signature peptides that could distinguish healthy
individuals from 3 different types of cancer patients. While all of
these peptides and/or their fragments are normally found in
the serum, differences in quantity between healthy and affected
individuals are observed. However, although these results
demonstrate the potential that peptidome profiles have for cancer
diagnosis, it still remains to be shown that this approach can be
extended to discover biomarkers suitable for early diagnosis and
consistent monitoring. First, the ability of these sera peptide
biomarkers to distinguish patients from controls was mostly
demonstrated for patients with highly advanced or metastatic
tumors. Moreover, the robustness of these biomarkers has been
challenged; uncontrolled variables, mostly attributed to differences
in sample handling, processing protocols and data analysis, have
been shown to dramatically modify the results of these assays
[11–19]. By putting major emphasis on sample acquisition,
handling, processing, MS signal processing and statistical analyses
more robust and reproducible results can be achieved [18,20,21].
In this work, we focused on discovering an array of signature
peptides that could have diagnostic value for stomach cancer. In
order to achievethis, we used three different serum sources involving
stomach cancer patients at different stages. A strict protocol for
serum collection and processing was applied [18], using a cohesive
procedure of peptide extraction and MALDI-TOF readings, with a
modified analysis pipeline. Together, the improved pipeline allowed
for the identification of a peptide pattern that discriminates between
cancer and control samples. These results were corroborated on the
original and new sera for three identified features from the pattern,
apoC-I (two features) and apoC-III, using immuno-based assays. We
then employed serum levels of apoC-I and apoC-III combined with
CRP and CA19-9markersto discriminate stomachadenocarcinoma
patients from cancer-free controls.
Materials and Methods
Serum harvesting and handling
Sera were obtained from two commercial sources. 79 sera
samples from pre-operation stomach cancer patients and 33 sera
samples from cancer-free matched controls (including 10 gastritis
patients) were collected by RNTech (Paris, France) in Romania.
Sera form cancer and non cancer patients were taken after
overnight fasting in the following manner: 5 ml of blood was drawn
into a vacuette serum tube (Cat #456005, Greiner Bio One,
Kremsmuenster, Austria) and left to clot for about 30 minutes, after
which the tube was centrifuged at 3,000 rpm on a Hettich EBA 20S
centrifuge (Hettich Ag, Tuttlingen, Germany) for 5 minutes at room
temperature. The separated serum was aliquoted into 1 ml aliquots
in sterile cryogenic tubes (Nalgene, Rochester, NY, USA) and
immediately frozen at (270)uC. 22 pre-operation stomach cancer
sera and 21 controls were collected by Asterand in the USA
(Detroit, MI, USA) in the following manner: 10 ml of blood was
drawn into a BD vacutainer SST plus plastic tube (cat #BEC
367985, BD, San Jose, CA, USA). The tube was mixed by inverting
it 5 times and left to clot for about 30 minutes in a vertical position.
This step was followed by a centrifugation of 1,100–1,300 g for 10
minutes at room temperature. The separated serum was aliquoted
into 1 ml aliquots in sterile cryogenic tubes (Nalgene) tubes and
immediately frozen at (270)uC. For the Asterand source, fasting
data was not collected on any of the blood draws in their bank. Sera
samples from both companies were transported on dry ice and
stored at (270)uC immediately upon arrival. Sera samples were
thawed on ice for about an hour and a half, 50 ml was aliquoted into
lo-bind tubes (Eppendorf, Hamburg, Germany) and immediately
re-frozen at (270)uC. All sample aliquots were stored at (270)uC
until processing. A third source of sera was obtained in our
laboratory from 12 cancer-free Israeli controls. Blood was drawn
with the tube brand used by RNTech (Cat #456005, Greiner Bio
One) and serum handling followed the procedure of RNTech. The
sera obtained in our laboratory were taken from non-fasting
individuals. Both RNTech and Asterand companies have estab-
lishedandconducted their activities followingregulatoryand ethical
standards, implementing local, national, European, US and
International (UN) rules and recommendations particularly when
applicable to biological material collection and treatment and
research result exploitation. This includes both written consent of
each patient contributing to the biological and data bank, and
written study authorization from the ethics committee of each
clinical institute contributing samples to the companies’ banks.
Serum sample processing and preparation for MS-MALDI
reading
Each serum sample was processed in two to three replicates
(from identical aliquots and on separate random dates). Peptides
were extracted on beads coated with C8, washed, eluted, mixed
with CHCA matrix, and deposited on the MALDI target plate.
Sera were processed in replicates and deposited onto the MALDI
plate in duplicates. For detailed description please see File S1.
Data analysis of MALDI results
Data processing was performed in two steps. In the first step, an
intensity matrix was performed from the raw ASCII files of
MALDI-TOF readings from all sera sample sources using re-
sampling, aligning, and m/z peaks detection as described in
Villanueva et al [21]. In the second step, machine learning was
used to define a discriminative pattern that can be used to classify
patients. For this purpose, the process described in Villanueva et al
[21] was modified as described below. The modified pipeline relies
entirely on open source software and additional details are
described in the bioinformatics section in File S1.
(1) A replicate summation and feature filter steps were added to
consider zero values as special cases. Our original matrix
contained a considerable amount of zero values for different
features in different samples. Due to general limitation of MALDI
technology, a significant fraction of these zero values could
represent missing values rather than true zero intensities. To
partially overcome this limitation we read each sample in
replicates, and calculated the average intensity, ignoring zero
intensity readings. Following this replicate summation, the resulted
matrix still contained substantial amount of zero values. SVM-
based models could classify according to zero values representing
missing values and not true zero intensities. Therefore, we filtered
out features that still had zero values in at least one of the samples.
None of these removed features had clear preference of zero values
to a specific clinical group assignment. The resulting sub-matrix
was used in a machine learning classification.
(2) A new approach to feature selection parameterization was
developed. The definitions for SVM-based analysis were initially
as follows: RNTech stomach vs. RNTech control, Asterand
stomach vs. Asterand control. Mann-Whitney p-value was
calculated for each peak, according to clinical groups defined for
the analysis. We then used Mann-Whitney p-values and peak
intensities as cutoffs to select a subset of features (peaks) for usage
in machine learning experiments. An intensity cutoff did not filter
ApoC-I and C-III as Biomarkers
PLoS ONE | www.plosone.org 2 January 2011 | Volume 6 | Issue 1 | e14540out samples in which at least one average reading had intensity
above the cutoff for the peak tested. Filter values were optimized
for best performance in SVM-based classifiers (produced by
LIBSVM, linear kernel) according to ten-fold cross validation by a
two-step protocol. The first step defined search ranges and
intervals for both filters and iterating over all combinations. Then,
the second step selected the combination of values, which provided
the best performance and smallest number of features.
(3) A normalization step was added to control for cross-sample
and cross-experiment biases. For sera sources’ comparison and
selection of features showing similar trends in both sources, cross-
source normalization of intensities was performed using the R
function ‘‘quantile’’ to define 9 thresholds X1.9 that divide the
scaled values in the control class into 10 quantiles.
Additional bioinformatics methods are provided in File S1.
Immuno-based commercial and clinical assays for the
different apolipoproteins
ApoC-III and apoB-100 levels were measured by Immunotur-
bidometry on an Olympus 400 autoanalyzer, using the K-assay
kits (cat # KAI-006 and 6142, Kamiya Biomedical, Seattle, WA,
USA) as previously described [22]. In house ELISA for apoC-III is
described in File S1. ApoC-I levels were tested using an AssayMax
Human Apolipoprotein C-I ELISA kit (Assaypro, St. Charles,
MO, USA) according to the manufacturer’s instructions. Purified
human apoC-I standards were included in the kit.
Results
Use of MS-based method to identify serum peptides
signature for stomach cancer
Previous studies showed that well-designed and carefully-
controlled sera peptidomics can separate specific cancer-bearing
patients and non-cancer controls based on distinctive patterns of
Table 1. Summary of clinical stages for stomach cancer and
cancer-free individuals’ sera from both sources.
Total samples (MALDI study, Clinical study)
Number of samples
Stage Asterand RNTech
Age
average Female Male
,IB 8 (8,8) 0 (0,0) 57 6 (6,6) 2 (2,2)
IB 3 (3,3) 7 (7,7) 68 8 (8,8) 2 (2,2)
II 4 (4,4) 25 (16,22) 66 14 (11,14) 15 (9,12)
IIA 0 (0,0) 11 (0,11) 65 1 (0,1) 10 (0,9)
IIIA 2 (2,1) 16 (8,15) 67 5 (2,4) 13 (8,12)
IIIB 0 (0,0) 7 (3,4) 66 2 (2,1) 5 (1,3)
IV 5 (5,4) 13 (6,11) 60 7 (5,5) 11 (6,10)
Stomach cancer 22 (22,20) 79 (40,70) 64 43 (34,39) 58 (28,50)
Controls 21 (21,19) 33 (20,33)* 54 28 (22,26) 26 (19,25)
Asterand and RNTech clinical stages, age average and gender for stomach
cancer and cancer-free individuals. The right and left values in parenthesis
indicate the number of samples used for MALDI and clinical studies,
respectively).
*RNTech control samples include 23 normal controls and 10 gastritis patients.
Clinical information for each individual is depicted in File S1. The supplemental
Tables include: sample ID, age at excision, sex, clinical diagnosis (specimen and
patient), AJCC/UICC TNM classification, AJCC/UICC stage group, CRP values and
CA 19-9 levels.
doi:10.1371/journal.pone.0014540.t001
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these results can be reproduced for stomach cancer and whether
such separation is sufficient for analysis of sera from different
sources. We first analyzed the serum peptide profiles of 62 patients
with stomach cancer at different stages, as well as 41 control sera
from healthy volunteers. These sera were obtained from two
sources: (i) RNTech, a company that collected sera at Bucharest,
Romania; and (ii) Asterand, a company that collected sera in the
USA. For each source, the sera were collected using a single
standard clinical protocol. The protocols were comparable e.g. the
type of the tube, the clotting time and the initial freezing of the
sera (see Methods), yet the blood withdrawal tubes were different.
Age distribution, gender, and clinical characteristics of the 103
individuals included in this study are provided in Table 1 and in
more detail in File S1. A summary of clinical stages of stomach
cancer-derived sera for both sources is given in Table 1. Sample
handling after the initial collection was uniform, involving 2
freeze-thaw cycles to accomplish initial storage and subsequent
aliquoting for peptide extraction and MS analysis. All 103 serum
samples were processed manually but identically employing one-
step reverse-phase extraction. Sera samples and sample replicates
were processed and read randomly on different dates to avoid
preparation date-associated bias. All sera preparation and
deposition was performed by the same individual. Similarly, all
MALDI readings were performed by the same technician. The
MALDI-TOF instrument’s sensitivity was monitored routinely
and constantly calibrated during all readings.
Analysis of MS-based sera peptidome revealed a
9-peptide signature that distinguish stomach
adenocarcinoma patients from cancer free controls
Total of 637 mass peaks (features) were identified in the 103
studied samples. The results of the MALDI were converted to a
matrix containing the signal intensities of 637 mass peaks (features)
for each of the studied serum samples with replicates for each
sample (see methods, bioinformatics). While unsupervised hierar-
chical clustering using all features did not segregate cancer and
non-cancer samples, PCA analysis of all features for each sera
source differentiated between cancer and non-cancer samples
(Figures S1–S3). This suggested that feature filtration and selection
is essential before employing machine learning-based classification.
Therefore we (i) applied a feature filtration and selection step and
(ii) employed Mann-Whitney p-values and peak intensities as
cutoffs to select a subset of features (peaks) for usage in machine
learning experiments. (see methods, bioinformatics). We then
analyzed within each source (RNTech and Asterand) whether sera
of patients and controls could be segregated. We received good
results for each of the single-source classifiers; SVM-based
classifiers for RNTech and Asterand had 90.0% and 93.0%
predicted accuracies, respectively, according to ten-fold cross
validation of the training set (Table 2A). Random shuffling of
group members resulted in much higher p-values (e.g. 0.8) and low
predicted accuracy in trained models per each sera source. This
indicated the significance of clinical conditions for classification
into two clinically-defined groups within each sera source.
However, the single-source classifiers did not perform well on
the other source’s samples, predicting correctly clinical status only
in 35/60 samples (Asterand on RNTech) and 25/43 (RNTech on
Asterand) (Table 2A). Therefore, source bias of peptidome has a
significant effect on the accuracy of prediction.
The inability of models trained on one source to adequately
predict clinical conditions from readings from the other source
(Table 2A) is better presented when checking the features selected
by the source-specific classifiers (Table 3). Some of the features
which worked well on one source showed an opposite trend on the
other source. Others were important for classification in one
Table 3. Peaks selected for models when quantile normalization was used before averaging and feature selection.
m/z Selected For Bias Dist Rn Bias Dist As Bias Dist Mix Possible identification
906 AM 12.44 4.017 V: m/z 905.5, FPA fragment FLAEGGGVR
1264 RM 77.57 1.935 V: m/z 1263.6, FPA fragment GEGDFLAEGGGVR
1351 R 260.86 V: m/z 1350.6, FPA fragment SGEGDFLAEGGGVR
1520 AR 16.73 26.35 V: m/z 1519.7, ITIH4 fragment GPPDVPDHAAYHPF
1534 A 212.59 V: m/z 1533.79, b-ion of c3f SKITHRIHWESASLL
1549 A 8.51 ?
4052 R 1.88 ?
4088 RM 228.53 2.666 EPO-KB: score 11, average m/z 4076.9, amyloid beta a4 protein
4207 RM 20.48 27.916 ?
5752 ARM 229.46 20.8 22.767 ?
5902 A 24.68 EPO-KB: score 3, average m/z 5902, fibrinogen alpha-chain frag.
6431 AM 12.57 2.799 EPO-KB: score 2.5, average m/z 6433.26, apolipoprotein C-I
6629 M 0.289 EPO-KB: score 5, average m/z 6624-6640, apolipoprotein C-I
9110 RM 13.08 26.08 EPO-KB: score 20, average m/z 9130, haptoglobin
9443 ARM 8.43 23.87 8.904 EPO-KB: score 0, average m/z 9443, apolipoprotein C-III
13997 A 6.73 ?
List of the classifier-selected peaks for Asterand-based classifier (A), RNTech-based classifier (R) and Mixed set-based classifier (M). Models studied data obtained when
quantile normalization was used before averaging and feature selection. The influence that each peak has on the prediction of the linear kernel SVM-based model was
evaluated by entering an zero values vector and comparing this result to that of a vector containing zeros in all but one peak which has the maximum possible value.
Directions were corrected so that signs would mean the same in all three models (minus: cancer; plus: control). Possible identification: Similar m/z values from the study
by Villanueva et al. [11] and EPO-KB (searchable knowledge base of biomarker to protein links) [34] are presented.
doi:10.1371/journal.pone.0014540.t003
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led us to a comparative analysis of data from both sources. We
produced box plots for all peak intensities, according to clinical
groups. These plots showed that when comparing control and
cancer intensities for each feature within a source, the trend
observed could differ between the two sources (e.g. m/z 1520,
Figure 1A). Even when the trend was persistent in both sources,
the intensity values could be different (e.g. m/z 6431; RNTech
higher than Asterand, Figure 1B). In order to create a prediction
model, we needed to (i) discard source-specific phenomena, and (ii)
add a normalization step which would reduce the effect of different
intensity levels where the trend was maintained.
The use of the mixed dataset with a Mann-Whitney p-value
cutoff for feature selection could discard source-specific phenom-
ena. Peaks which showed different trends in different sources
would not be significant in the mixed set for clinical group-based
separation; feature 1520 manifesting opposite trend between
sources, was selected by each single source classifier (Figure 1A,
Table 3). Therefore, it contributed to the lack of successful
performance of each single source classifier on the other source
(Table 2A). As expected, this feature was not selected by any
model based on the mixed set. We created a mixed data set while
randomly removing 21 stomach cancer samples from the mixed
training set, and used these 21 removed samples for validation. In
addition, we used the 12 cancer-free control samples collected in
our laboratory as an independent control validation set. The
model was selected in keeping with a maximum predicted
accuracy according to a ten-fold cross validation, as before. The
best scoring model for the mixed set was using 9 features (Mann-
Whitney p-value filter of 0.044) and had a predicted accuracy of
84.1% according to ten-fold cross validation of the training set.
Importantly, it accurately predicted 10/12 Israeli controls.
However, this classifier predicted inadequately (13 of 21) the 21
removed mixed stomach cancer samples used for validation.
Therefore, to reduce the effect of source-related differences in
intensity levels, the filter’s performance in feature selection was
enhanced by introducing a quantile normalization step. This
normalization was performed according to controls of each sera
source independently of the other sources (see methods, bioinfor-
matics). For features, such as m/z 6431 with a persistent trend in
both sources, this step corrected the intensity bias (Figure 1D).
Indeed, 6431 feature was not selected for the non-normalized mix-
Figure 1. Boxplot presentations of features 1520 (A, C) and 6431 (B, D). A and B represent non-normalized peak intensities; C and D
represent intensities following quantile normalization according to controls of each sera source (see methods). Rn, RNTech; As, Asterand.
doi:10.1371/journal.pone.0014540.g001
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based classifier (Table 3). Yet, for features such as m/z 1520 with
opposite trends in both sources, this step could not change the
trend, as expected (Figure 1C).
We tested the quantile normalization’s effect by applying it
before averaging and feature selection. To better assess the
prediction accuracy we employed the Matthews Correlation
Coefficient (MCC) measure. MCC is used in machine learning
as a measure of the quality of binary (two class) classifications and
returns a value between 21 and +1. A coefficient of +1 represents
a perfect prediction, 0 an average random prediction and 21a n
inverse prediction. MCC is generally regarded as a balanced
measure which can be used even if the classes are of different sizes.
We thus calculated the MCC for various classification experiments
in order to show the effect that normalization had on classification.
Results are shown in Table 2. Note that without normalization,
MCC was relatively high for the training set, yet showed mediocre
performance on the validation set (Table 2). The normalization
step gave similar high MCC values for training and validation sets
(Table 2). The normalization step to control cross-source bias did
not annul the need for machine learning-based classifier to define
a discriminative pattern; PCA of the two sources-mixed normal-
ized data sets resulted again in poor separation between stomach
cancer and control samples (Figure S4).
Immuno-based validation for features representing
apoC-I and apoC-III
The classifier resulted from the mixed data set, following
quantile normalization step, employed 9 features (Table 2). Three
of the 9 features involved apolipoproteins: apoC-III (feature 9443)
and apoC-I (features 6431 and 6629, Table 3). To further verify
the MALDI-based results, we first developed an ELISA test for the
qualitative detection of apoC-III in the serum (see methods) and
tested all sera samples from Asterand and RNTech. Results of the
ELISA followed the trend of the MALDI results (Figure 2A, B);
Intensity of the apoC-III was significantly higher in control groups
as compared to cancer groups in both sera sources. We further
assayed the correlation between apoC-III ELISA and 9443
MALDI results per each sample; ELISA and MALDI results
showed significant correlation (p,0.0001, Kendall’s ran correla-
tion tau). We then sent sera aliquots from nearly all samples (same
freeze state) to an external clinical laboratory for immunoturbid-
ity-based quantitative assay for apoC-III [22]. Results were
obtained in mg/dl (Figure 2C) and as above, quantity of apoC-
III was significantly higher in control groups of both sera sources.
To verify the apoC-I MALDI results, we employed a
commercial quantitative ELISA kit that includes apoC-I standards
and recognizes both 6431 and 6629 variants of apoC-I. Results
were obtained in mg/ml (Figure 3B) and followed the pattern
observed for the MALDI results (Figures 1D and 3A); Intensity of
the apoC-I was significantly higher in control groups as compared
to cancer groups in both sera sources. To assess the specificity of
apoC-I and apoC-III reduction in the sera of stomach cancer-
Figure 2. Boxplot presentations of MALDI feature 9443 and
apoC-III ELISA assay. Boxplot presentations of MALDI feature 9443
(A), qualitative ELISA assay for apoC-III (B) and quantitative immuno-
turbidity-based assay for apoC-III (C). For A, units represent MALDI-
based intensities following quantile normalization according to controls
of each sera source (see methods). For B, units represent OD ratios of
apoC-III ELISA following normalization to the average of controls of
each sera source. For C, units represent apoC-III concentration in sera.
For RNTech (Rn), * p-value ,0.0001 for A and B, and ,0.05 for C. For
Asterand (As), * p-value ,0.01 for A and B, and =0.06 for C; Wilcoxon
rank sum test with continuity correction (alternative hypothesis: true
location shift is greater than 0).
doi:10.1371/journal.pone.0014540.g002
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for apoC-III in the external clinical laboratory were assayed in
parallel for apoB-100 levels using immunoturbidity-based quan-
titative assay. Results were obtained in mg/dl (Figure 3C) and
showed no significant trend between control and stomach cancer-
bearing groups. Therefore, we could make use of the apoB-100
results as a normalizing factor for the bioinformatics analysis of the
quantitative apoC-I and apoC-III results (Figures 3C, 3B, 2C,
respectively).
We analyzed clinically apoC-I, apoC-III and apoB-100 for
additional samples from stomach cancer patients and cancer-free
controls (RNTech source, same freeze-state; including 10 gastritis
patients in the cancer-free controls; note Table 1 for the total
sample numbers). We also analyzed clinically CA19-9 and CRP
levels for all samples (same freeze-state). We then employed
Clementine 10.0 software on the RNTech samples to assess
whether rules set based on apoB-100-normalized C-I and C-III,
CA19-9 and CRP serum levels can be used to classify between sera
of control and stomach cancer groups of RNTech source as a
training source. The combination of all 4 parameters yielded
better prediction accuracy as compared to combination of less
than 4 parameters (Figure 4 and data not shown). Prediction
accuracy of the training set was 88.4%. We employed the
RNTech-obtained rules set for the Asterand source and prediction
accuracy was 74.4% (Figure 4). For both training and validation
the sensitivity was excellent (87/90 combined) but the specificity
was less accurate (37/52 combined).
Discussion
In recent years, quite a few reports describing MS-identified
serum biomarkers/signatures for cancerous states were proven
wrong [5,18]. Different sources of bias were described including
sample selection, handling, processing, reading and analyzing
[18,20,21]. Upon removal of bias-contributing factors, it was
shown that SELDI-TOF MS whole serum proteomic profiling
with IMAC surface did not reliably detect prostate cancer [23].
Therefore, the authors suggested that it is unlikely that a mass
spectrometry approach using unprocessed serum would differen-
tiate between men with and without prostate cancer [24]. On the
other hand, other recent MALDI-TOF-based studies that avoided
bias-contributing factors and employed a one-step sera processing
technique identified discriminating biomarker signatures for
different cancers including prostate cancer [11].
In this study we adopted the one step sera processing approach
for identification of a peptidome-based signature to differentiate
sera derived from stomach adenocarcinoma patients. We made a
reasonable effort to avoid previously-reported bias contributing
factors [18]. We analyzed sera from two biorepositories. We
observed that even when sera handling, processing, MALDI
reading and analysis are the same, peptidome analysis is biased by
the biorepository. In addition to the socio-geographical differences
(Romania and USA as the source for the samples in RNTech and
Asterand, respectively), the source-related bias could be due to the
Figure 3. Boxplot presentations of MALDI feature 6629 and
apoC-I and apoB-100 ELISA assay. Boxplot presentations of MALDI
feature 6629 (A), quantitative ELISA assay for apoC-I (B) and quantitative
immunoturbidity-based assay for apoB-100 (C). For A, units represent
MALDI-based intensities following quantile normalization according to
controls of each sera source (see methods). For B and C, units represent
apoC-I and apoB-100 concentration in sera, respectively. For RNTech
(Rn), * p-value =0.002 for A and ,0.0001 for B. For Asterand (As),
* p-value ,0.05 for A and =0.001 for B; Wilcoxon rank sum test with
continuity correction (alternative hypothesis: true location shift is
greater than 0).
doi:10.1371/journal.pone.0014540.g003
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biorepositories.
We then used a mixed sample set from two sera sources for
feature selection and added a cross-source normalization step to
compensate for source bias. We found that (i) the use of the mixed
dataset with a Mann-Whitney p-value cutoff for feature selection
could discard source-specific features, and (ii) a quantile normali-
zation step helps to select (for machine learning) partially
concordant features, in which the trends are concordant between
sources, but intensity levels are different between sources. The need
for normalization, when dealing with samples from different
sources, was already shown for microarray-based high throughput
technology [25]. It is well established that variations in experimental
procedures and uncontrolled conditions (e.g. socio-geographical
origin of samples) may lead to systemic measurement biases.
Following the modifications, we established a cross-source
serum peptide signature for distinguishing stomach cancer patients
from non-cancer controls. Three of the peptides corresponded to
apoC-I and apoC-III. We validated our MALDI-based results
with independent analytical methods that are based on immuno-
assays [26]. The peptide signature included apoC-III and apoC-I-
derived features. The results from independent quantification of
their serum levels followed the trend identified by the MS
approach.
Our study is the first to report that serum levels of apoC-I and
apoC-III can be used as potential biomarkers for stomach cancer.
It is true that recent reports have indicated that apolipoproteins’
levels in blood could be potential biomarkers for different
cancers. ApoC-I was identified as a potential serum biomarker
for colorectal cancer, hormone-refractory prostate cancer and liver
Figure 4. Decision tree for stomach cancer patients prediction and accuracy of prediction. (A) Accuracy of prediction produced by
decision trees using (1) apoC-I/apoB-100 and apoC-III/apoB-100; (2) CRP (mg/ml) and CA19-9 (U/ml); and (3) apoC-I/apoB-100, apoC-III/apoB-100, CRP
(mg/ml) and CA19-9 (U/ml) over training set RNTech and testing set Asterand. (B) Decision tree using the 4 features apoC-I/apoB-100, apoC-III/apoB-
100, CRP (mg/ml) and CA19-9 (U/ml).
doi:10.1371/journal.pone.0014540.g004
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be a potential biomarker in pancreatic cancer and breast cancer
[30,31]. However, all of these reports employed MALDI-based
screening and did not verify their results with immuno-based or
other assays. Nor did they study sera from another source as a
validation group.
Our findings should be further expended and validated as
described [32,33]. Yet, the clinical validation of apoC-I and apoC-
III results prompt us to further explore a diagnostic assay based on
serum biomarkers that could be assayed in the clinic without the
need for MS technology. Rules set utilizing apoB-100-normalized
C-I and C-III, CA19-9 and CRP quantitative serum levels
generated for the RNTech source and validated on the
independent Asterand source had prediction accuracy of 88.4%
and 74.4%, respectively. Therefore, the use of these 4 clinical
features partially overcomes the source bias. However, the
relatively lower specificity indicates that additional clinical
parameter(s)/serum biomarkers should be added for the formu-
lation of an applicable diagnostic score for stomach cancer
patients. Additional source for such biomarkers could be
differential glycosylation of secreted proteins that could provide
additional serum biomarkers for cancerous state [35,36].
Supporting Information
File S1 Supplemental methods (bioinformatics, MALDI - serum
preparation and reading). Supplemental results (hierarchical
clustering and PCA). Legends to Figures S1 to S4 (showing
hierarchical clustering and PCA). Tables S1 to S3, showing age
distribution and gender, and clinical characteristics, are provided:
Tables S1 (RNTech), S2 (Asterand) and S3 (Israeli controls).
Found at: doi:10.1371/journal.pone.0014540.s001 (0.30 MB
DOC)
Figure S1 Principal Components Analysis (PCA) on data
derived from RNTech sera (A), Asterand sera (B), and the mixed
(RNTech and Asterand) dataset (C). For A and B, blue and red
circles indicate control and stomach samples, respectively. For C,
green and red circles indicate Asterand control and stomach,
respectively; black and blue indicate RNTech control and
stomach, respectively.
Found at: doi:10.1371/journal.pone.0014540.s002 (0.24 MB TIF)
Figure S2 Unsupervised hierarchical clustering on data derived
from RNTech sera (A) and Asterand sera (B). For A, blue and
black indicate cancer and control samples, respectively. For B, red
and green indicate cancer and control samples, respectively.
Found at: doi:10.1371/journal.pone.0014540.s003 (1.94 MB TIF)
Figure S3 Unsupervised hierarchical clustering on data derived
from the mixed (RNTech and Asterand) dataset. For the RNTech
samples set, blue and black indicate cancer and control samples,
respectively. For the Asterand samples set, red and green indicate
cancer and control samples, respectively.
Found at: doi:10.1371/journal.pone.0014540.s004 (5.63 MB TIF)
Figure S4 Principal Components Analysis (PCA) on the
normalized mixed (RNTech and Asterand) dataset. Green and
red circles indicate Asterand control and stomach, respectively;
black and blue indicate RNTech control and stomach, respec-
tively.
Found at: doi:10.1371/journal.pone.0014540.s005 (0.07 MB TIF)
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